Intelligent Bio Solutions Inc. Announces Public Stock Offering
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a pioneer in medical technology focused on non-invasive testing solutions, made a significant announcement regarding a public offering of its common stock. While the company is excited about moving forward, it emphasizes that the offering is contingent upon market conditions, which means the completion date, size, and terms remain uncertain.
Details of the Stock Offering
The entire offering is being conducted by Intelligent Bio Solutions Inc. itself, with Ladenburg Thalmann & Co. Inc. acting as the sole bookrunning manager, poised to guide and facilitate the process.
Regulatory Framework
This move is in alignment with a shelf registration statement that was filed with the Securities and Exchange Commission in the past. This regulatory filing is crucial as it paves the way for the offering, ensuring compliance with legal standards set forth by the SEC, which is vital for any public capital-raising efforts.
Prospective Investors and Information Availability
A preliminary prospectus supplement detailing the offering will soon be made available, guiding potential investors through the specifics of the offering. Interested parties will be able to find the document on the SEC’s official site. Additionally, copies may be obtained by reaching out directly to Ladenburg Thalmann & Co. Inc.
Commitment to Transparency
It is imperative for Intelligent Bio Solutions Inc. to stress that this announcement does not constitute an offer to sell or solicit an offer to buy securities in jurisdictions where such actions would be illegal prior to registration under the relevant securities laws.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. is at the forefront of transforming medical technology through its innovative Intelligent Fingerprinting Drug Screening System. This groundbreaking system analyzes fingerprint sweat to provide rapid and accurate drug screenings, with results available in under ten minutes. This efficiency makes their solution ideal for organizations in need of quick, reliable testing, particularly in industries like construction and transport. The company has a diverse customer base outside the US, including sectors that support safety and compliance.
The Future of Drug Testing
With its cost-effective and hygienic testing protocol, Intelligent Bio Solutions Inc. is positioning itself as a leader in portable drug screening technology. The potential for broader applications beyond the current scope showcases the company's commitment to innovation and excellence.
Company Contact
If you have any inquiries or require further information, Intelligent Bio Solutions Inc. can be reached via their official email.
info@ibs.inc
Investor Relations
For any investor-related questions, contact Valter Pinto, Managing Director at KCSA Strategic Communications. You can reach him directly at (212) 896-1254 or through their official investor email.
Frequently Asked Questions
What is the purpose of the public offering by Intelligent Bio Solutions Inc.?
The public offering aims to raise funds to enhance the company's innovative medical technology solutions, focusing on non-invasive testing.
Who is managing the public offering?
Ladenburg Thalmann & Co. Inc. is the sole bookrunning manager for the offering, ensuring a smooth capital-raising process.
How will investors obtain the offering's prospectus?
The preliminary prospectus will be filed with the SEC and will also be available through formal requests to the managing broker.
What technology does Intelligent Bio Solutions Inc. provide?
The company specializes in non-invasive drug testing technology through its Intelligent Fingerprinting Drug Screening System.
What sectors does Intelligent Bio Solutions Inc. cater to?
The company serves a variety of customer segments, including construction, engineering, and transport sectors that require reliable drug screening solutions.
